Molecular Targeted Cancer Therapies-Can anything else revolutionize the market?

Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.

329 different pipeline candidates have been identified of which 24 are in late-phase development. These identified candidates have a forecast sales potential of up to $6.03 billion in the seven major pharmaceutical markets by 2016.

Among agents with the greatest commercial potential are the angiogenesis inhibitors Recentin (cediranib; AstraZeneca), aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and pazopanib (GlaxoSmithKline).

Other candidates holding particular promise include the only preregistered agent Novartis's Gleevec-follow-on Tasigna (nilotinib), Novartis's mTOR inhibitor Certican (everolimus), and Biogen Idec's anti-CD23 monoclonal antibody, lumiliximab.

Read more...

• Obesity Drug Markets (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)

• Cardiovascular market overview (19/05/2008)
• Hepatitis B (16/05/2008)
• Substance Dependence - Part I (16/05/2008)
• Orphan Diseases in CNS - Part I (16/05/2008)
• Head and Neck Cancer (16/05/2008)
• Prostate Cancer (16/05/2008)
• Parkinson's Disease (16/05/2008)
• Inflammatory Bowel Disease (16/05/2008)
• Endometriosis (16/05/2008)

---